What is Gero?
Gero operates with a physics-first approach to AI drug discovery and development, focusing on age-related diseases and the aging process itself. The company's proprietary platform constructs AI models of human health by integrating large-scale longitudinal real-world data, encompassing clinical, molecular, omics, and genetic information. This is combined with physics-based modeling and AI-driven target discovery. A key component of their technology is ProtoBind-Diff, a generative AI model capable of designing small molecules directly from protein sequences. Gero collaborates with pharmaceutical entities on age-related disease initiatives and simultaneously advances its own programs aimed at intervening in the aging process. The company's scientific contributions have been recognized through publications in prestigious journals such as Science and Nature Communications. Gero is headquartered in Singapore, with a U.S. presence in San Francisco.
How much funding has Gero raised?
Gero has raised a total of $25.2M across 2 funding rounds:
Series A
$8.2M
Other Financing Round
$17M
Series A (2023): $8.2M with participation from Melnichek Investments and Bulba Ventures
Other Financing Round (2026): $17M led by Melnichek Investments
Key Investors in Gero
Melnichek Investments
Melnichek Investments is dedicated to enhancing human life by funding and supporting innovative machine learning and biotech startups. The company leverages its own funds, derived from the successful acquisition of Vochi, to empower talented founders and their projects. Notable initiatives include Gero, which focuses on therapeutics for chronic diseases, and Doctorina, an AI-driven platform for healthcare management. Melnichek Investments seeks to collaborate with visionary minds and groundbreaking ideas to drive progress in various sectors.
Bulba Ventures
Bulba Ventures is an investment firm that has participated in funding rounds for Gero. Further details on their specific investment focus or domain are not publicly available.
Undisclosed Investor
An undisclosed investor participated in this funding round, contributing to Gero's overall capital.
What's next for Gero?
With the recent major strategic investment, Gero is poised to accelerate its innovative research and development in AI-driven drug discovery for age-related conditions. This significant backing, part of its $25.2M in total capital, will likely fuel the expansion of its proprietary programs targeting the biology of aging and enhance its partnerships within the pharmaceutical sector. The company's focus on integrating physics-based modeling with advanced AI, particularly its generative model for small-molecule design, positions it for continued leadership in a rapidly evolving field. Future endeavors will probably involve further validation of its platform's efficacy and the progression of its therapeutic candidates through development pipelines.
See full Gero company page
